t:slim X2 Becomes First Automated-Insulin-Delivery System to Fully Integrate With the FreeStyle Libre 2 Plus CGM

On January 8, 2024, Abbott announced that the t:slim X2 insulin pump automated-insulin delivery (AID) system became the first AID system to integrate with the FreeStyle Libre 2 Plus continuous glucose monitoring CGM system.

This is a huge access win for patients, especially existing Libre users who are insulin-dependent. 

What t:slim X2  Integrating with Freestyle Libre 2 Means for People with Diabetes

For the first time, FreeStyle Libre 2 Plus users in the United States can experience the benefits of a hybrid, closed-loop insulin system to help predict and prevent both high- and low blood-sugar levels. 

The t:slim X2 insulin pump wirelessly integrates with Bluetooth technology to the Freestyle Libre CGM system, which sends blood-sugar level updates every minute to the insulin pump.

Users can view their blood-sugar-level data on either their insulin pump or t:connect—the accompanying mobile app. 

The FreeStyle Libre 2 Plus is Abbott’s newest technology that was specifically approved by the Food and Drug Administration for use with AID insulin-pump systems in 2023. 

The FreeStyle Libre 2 Plus is also the first and only CGM available in the US with a wear time of 15 days for both children and adults. 

“Our FreeStyle Libre portfolio empowers people living with diabetes to have more control over their health and eases the burden of their condition by using a continuous glucose monitoring system with unsurpassed accuracy that is simple, easy and affordable to use,” said Jared Watkin, executive vice president of Abbott’s diabetes care business. “Through the integration of Tandem’s t:slim X2 insulin pump with our FreeStyle Libre 2 Plus sensor, people only need two sensors a month, which ensures both a more convenient and more affordable experience.”

The Control-IQ technology predicts blood-sugar levels thirty minutes into the future, automatically adjusting insulin delivery every five minutes based on blood-sugar level readings from the CGM.

It can also automatically deliver correction boluses of insulin of up to one per hour to prevent high blood-sugar levels. 

John Sheridan, president and chief executive officer of Tandem Diabetes Care said in a statement, “Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the United States. This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for people living with diabetes.”

With these two powerful systems integrated, people with diabetes—especially existing Libre users who take insulin—will experience more ease and efficiency with their diabetes management than ever before. 

What is the Availability in the United States? 

Tandem Diabetes Care will send out instructions via email to all in-warranty t:slim X2 users in the United States offering the option to add the new FreeStyle Libre 2 Plus integration at no cost with a remote software update. 

T:slim X2 pumps for new customers will now also be shipped with the updated software pre-loaded into the system.

More information about the software update process for existing in-warranty pump users, including system requirements, is available at tandemdiabetes.com/softwareupdate.

For more information on accessing the t:slim X2 insulin pump and FreeStyle Libre 2 Plus sensor integration, please visit tandemdiabetes.com/products.

This content was made possible by Abbott, a Founding Partner of Beyond Type 1.

Beyond Type 1 maintains editorial control over its content.